We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M Turnover 71.43%
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$954M
AUM Growth
+$43.5M
Cap. Flow
-$47.3M
Cap. Flow %
-4.96%
Top 10 Hldgs %
75.65%
Holding
29
New
6
Increased
8
Reduced
7
Closed
5
Avg Time Held
0.8 years
Top 10 Avg Time Held
0.4 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
CORT icon
Corcept Therapeutics
CORT
+$45.4M
2
AAAP icon
Advanced Accelerator Applications S.A.
AAAP
+$45.3M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$36.3M
4
GMED icon
Globus Medical
GMED
+$29.3M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$84.9M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$44.2M
3
MD icon
Pediatrix Medical
MD
+$44M
4
MACK icon
Merrimack Pharmaceuticals, Inc.
MACK
+$37M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$91.9M 9.63%
6,218,903
+425,000
+7% +$6.88M
2016 Q3
2 quarters
UTHR icon
2
United Therapeutics
UTHR
$22.9B
$86.9M 9.11%
642,168
+61,467
+11% +$9.31M
2016 Q2
3 quarters
GMED icon
3
Globus Medical
GMED
$10.4B
$86.9M 9.11%
2,935,000
+1,075,000
+58% +$29.3M
2016 Q3
2 quarters
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$85M 8.91%
1,334,467
-1,396,420
-51% -$84.9M
2016 Q2
3 quarters
AMRN icon
5
Amarin Corp
AMRN
$238M
$80.2M 8.4%
1,252,619
– –
2016 Q3
2 quarters
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$69.5M 7.28%
1,558,944
+405,000
+35% +$20M
2015 Q4
5 quarters
MYGN icon
7
Myriad Genetics
MYGN
$386M
$57.1M 5.99%
2,976,356
+647,424
+28% +$11.5M
2016 Q3
2 quarters
CORT icon
8
Corcept Therapeutics
CORT
$11.7B
$56.7M 5.94%
+5,169,640
New +$45.4M
2017 Q1
0 quarters
ATRC icon
9
AtriCure
ATRC
$2.86B
$55.3M 5.79%
2,886,354
+220,000
+8% +$3.85M
2016 Q3
2 quarters
AAAP icon
10
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$52.3M 5.48%
+1,311,855
New +$45.3M
2017 Q1
0 quarters
PCRX icon
11
Pacira BioSciences
PCRX
$1.45B
$44.3M 4.65%
972,535
+340,730
+54% +$14.7M
2016 Q4
1 quarter
LJPC
12
DELISTED
La Jolla Pharmaceutical Company
LJPC
$42.4M 4.44%
+1,420,742
New +$36.3M
2017 Q1
0 quarters
TVTX icon
13
Travere Therapeutics
TVTX
$4.7B
$39.4M 4.13%
2,132,140
-640,016
-23% -$12.5M
2014 Q3
10 quarters
NVDQ icon
14
DELISTED
Novadaq Technologies Inc.
NVDQ
$23.5M 2.46%
3,018,179
+605,000
+25% +$4.29M
2016 Q4
1 quarter
CVRS
15
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$19.8M 2.08%
+15,114,872
New +$12.3M
2017 Q1
0 quarters
ACHC icon
16
Acadia Healthcare
ACHC
$2.8B
$13.5M 1.42%
310,666
-200,000
-39% -$8.12M
2016 Q4
1 quarter
ACOR
17
DELISTED
Acorda Therapeutics
ACOR
$13M 1.36%
+5,162
New +$14.9M
2017 Q1
0 quarters
ARRY icon
18
DELISTED
Array Biopharma Inc
ARRY
$12.3M 1.29%
1,373,471
-1,350,000
-50% -$14.4M
2016 Q4
1 quarter
VCEL icon
19
Vericel Corp
VCEL
$2.06B
$8.35M 0.88%
2,982,940
– –
2014 Q3
10 quarters
ANIP icon
20
ANI Pharmaceuticals
ANIP
$1.65B
$7.08M 0.74%
143,003
-348,605
-71% -$19.6M
2014 Q1
12 quarters
ADMA icon
21
ADMA Biologics
ADMA
$2.39B
$6.22M 0.65%
1,273,933
– –
2014 Q4
9 quarters
BIOL icon
22
DELISTED
Biolase, Inc.
BIOL
$1.7M 0.18%
101
-15
-13% -$272K
2015 Q2
7 quarters
SPNE
23
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$692K 0.07%
88,127
-40,000
-31% -$289K
2015 Q3
6 quarters
SBBP
24
DELISTED
Strongbridge Biopharma plc.
SBBP
$48K 0.01%
+10,000
New +$30.6K
2017 Q1
0 quarters
MD icon
25
Pediatrix Medical
MD
$2.21B
– –
-660,000
Closed -$44M –
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Consonance Capital Management held 29 positions worth $954M, up 4.8% from $911M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Consonance Capital Management withdrew a net $47.3M in Q1 2017, closing 5 positions and reducing 7 holdings. Its most notable exit was Ariad Pharmaceuticals Inc, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Corcept Therapeutics worth $56.7M.

  • Consonance Capital Management's largest Q1 2017 buy was Corcept Therapeutics: 5,169,640 shares worth $56.7M.
  • Consonance Capital Management added most to Globus Medical in Q1 2017, an estimated $29.3M increase.
  • Consonance Capital Management's biggest Q1 2017 reduction was Clovis Oncology, Inc., cutting an estimated $84.9M.
  • Consonance Capital Management fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $44.2M.
  • Consonance Capital Management's ten largest holdings make up 76% of its $954M portfolio in Q1 2017.
  • Consonance Capital Management opened 6 new positions and closed 5 in Q1 2017.
  • Consonance Capital Management's portfolio value rose 4.8% quarter-over-quarter to $954M.

Based on Consonance Capital Management's 13F filing for Q1 2017, filed 15 May 2017.